Organization | Rajaie Cardiovascular Medical and Research Center

Rajaie Cardiovascular Medical and Research Center Report issue

Academic/Hospital Phase 3

Founded: Tehran Iran (Islamic Republic of) (1973)

Organization Overview

First Clinical Trial

2016

NCT05223361

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Rajaie Cardiovascular Medical and Research Center

Active Ingredients

Drugs in Phase 3 Trials (12)

acetylcysteine (mucomyst) (1 trial)

atorvastatin (lipitor) (1 trial)

empagliflozin (jardiance) (1 trial)

enoxaparin (lovenox) (2 trials)

fludrocortisone (florinef) (1 trial)

hydroxyethyl starch (voluven) (1 trial)

midodrine (proamatine) (1 trial)

ringer's lactate (1 trial)

rivaroxaban (xarelto) (2 trials)

unfractionated heparin (1 trial)

vitamin e (1 trial)

warfarin (coumadin) (2 trials)

Drugs in Other Trials (2)

ivabradine (corlanor) (1 trial)

metoprolol (lopressor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Coronary Syndrome (Phase 3)

Acute Kidney Injury (Phase 3)

Angina, Stable (Phase 3)

Atrial Fibrillation (Phase 3)

Constriction, Pathologic (Phase 3)

Coronary Artery Disease (Phase 3)

Heart Diseases (Phase 3)

Mitral Valve Stenosis (Phase 3)

Rheumatic Heart Disease (Phase 3)

Syncope (Phase 3)

Syncope, Vasovagal (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial APIs: 14